Economic aspects of medical erectile dysfunction therapies

Author： Anastasiadis Aristotelis G Ghafar Mohamed A Shabsigh Ridwan Burchardt Martin

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.3, Iss.3, 2002-03, pp. : 257-263

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Looking to the Future for Erectile Dysfunction Therapies

By Hatzimouratidis Konstantinos Hatzichristou Dimitrios G.

Drugs, Vol. 68, Iss. 2, 2008-01 ,pp. : 231-250

Adis International

Access to resources Recommend Favorite

Emerging pharmacological therapies for erectile dysfunction

By Gingell J. Lockyer R.

Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 12, 1999-12 ,pp. : 1689-1696

Informa Healthcare

Access to resources Recommend Favorite

The Triumvirate of Erectile Dysfunction Therapies: Is There Room for Three?

Pharmaceutical & Diagnostic Innovation, Vol. 1, Iss. 3, 2004-01 ,pp. : 21-23

Adis International

Access to resources Recommend Favorite

Emerging Molecular Targets for Treatment of Erectile Dysfunction: Vascular and Regenerative Therapies on the Horizon

Current Drug Targets, Vol. 16, Iss. 5, 2015-05 ,pp. : 427-441

Bentham Science Publishers

Access to resources Recommend Favorite

The EMEA's CHMP has recommended the contraindication of certain erectile dysfunction therapies in patients with single-eye vision loss

Reactions Weekly, Vol. 1, Iss. 1102, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite